ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sarepta licenses Summit’s DMD drugs

by Lisa M. Jarvis
October 10, 2016 | APPEARED IN VOLUME 94, ISSUE 40

In its second partnership since FDA approval last month of eteplirsen, its exon-skipping Duchenne muscular dystrophy treatment, Sarepta Therapeutics has licensed the European rights to Summit Therapeutics’ utrophin modulator pipeline. The deal includes ezutromid, which is in a Phase II study for treating DMD. Summit will get $40 million up front and could reap another $522 million in milestone payments. Late last month, Sarepta teamed with Catabasis to study combining its exon-skipping drugs with Catabasis’s NF-κB inhibitors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment